REABOURNE MERLIN LIFE SCIENCES INVESTMENT TRUST PLC
21 September 1999
REABOURNE MERLIN LIFE SCIENCES INVESTMENT TRUST PLC
('RMLIT' or the 'COMPANY')
CHANGE OF NAME AND INCREASED BORROWING POWERS
RMLIT announces that, at an extraordinary general meeting of the Company held
on 21 September 1999, shareholders approved all resolutions enabling the
Company to change its name to 'Finsbury Life Sciences Investment Trust PLC' and
borrow up to £6,000,000 over the medium term for investment purposes.
John Sclater, chairman of the Company, said 'The Board is pleased to announce
that these proposals have received approval. The Board believes that with the
improving sentiment towards the Life Science sector and the attractive
potential returns that Life Science companies can offer the introduction of an
element of gearing to the Company should enhance potential returns to
shareholders over the medium term. The rebranding of the Company will further
raise its profile and will allow it to derive marketing benefits from being
more closely associated with the Finsbury name.'
Enquiries:
John Sclater 0171 623 1155
Chairman
David Fallon 0171 397 6987
Finsbury Asset Management
Andrew Zychowski 0171 623 8000
Dresdner Kleinwort Benson
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.